Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma

Table 1 Comparison of baseline clinical data between Group A and Group C

	Group A (n = 40)	Group C (n = 40)	t/χ2 value	P value
Gender (Male)	29	31	0.267	0.606
Age (yr)	62.82 ± 12.93	61.38 ± 10.29	0.551	0.583
Tumor size (cm)	3.75 ± 1.21	3.68 ± 1.17	0.263	0.793
Number of tumors			0.050	0.823
Single	22	21
2-3	18	19
Child-Pugh classification			0.054	0.816
A	26	25
B	14	15
TBiL (μmol/L)	18.28 ± 5.28	17.83 ± 5.16	0.583	0.562
AFP (ng/ml)	612.29 ± 127.38	625.93 ± 139.27	0.457	0.649
ALB (g/L)	37.19 ± 5.39	36.93 ± 5.33	0.217	0.829
ALT (U/L)	35.27 ± 15.14	36.42 ± 17.46	0.315	0.754
AST (U/L)	38.63 ± 15.13	40.41 ± 16.52	0.503	0.617

AFP: Alpha-fetoprotein; ALB: Serum albumin; ALT: Aminotransferase; AST: Aspartate aminotransferase; TBiL: Total bilirubin.